OraSure Technologies, Inc. (NASDAQ:OSUR) Receives $10.00 Consensus PT from Brokerages

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) have earned an average rating of “Hold” from the six analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation and two have issued a hold recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $10.00.

Several research analysts have commented on OSUR shares. Zacks Investment Research raised shares of DLH from a “sell” rating to a “hold” rating in a research note on Tuesday, July 9th. Canaccord Genuity reissued a “hold” rating and set a $20.00 price target (down from $29.00) on shares of Sailpoint Technologies in a research note on Thursday, May 9th. Finally, BidaskClub raised shares of Zai Lab from a “sell” rating to a “hold” rating in a research note on Wednesday, June 5th.

OSUR traded down $0.02 on Friday, reaching $8.47. The company had a trading volume of 15,691 shares, compared to its average volume of 699,242. The business has a 50 day moving average of $8.73. The stock has a market capitalization of $530.53 million, a P/E ratio of 17.10, a price-to-earnings-growth ratio of 2.97 and a beta of 1.21. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.56 and a current ratio of 7.52. OraSure Technologies has a 52-week low of $8.01 and a 52-week high of $17.32.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The business had revenue of $30.12 million for the quarter, compared to the consensus estimate of $29.66 million. OraSure Technologies had a net margin of 11.34% and a return on equity of 7.87%. OraSure Technologies’s quarterly revenue was down 28.3% on a year-over-year basis. During the same period last year, the firm posted $0.07 earnings per share. On average, equities analysts expect that OraSure Technologies will post 0.23 EPS for the current fiscal year.

In other OraSure Technologies news, SVP Jack E. Jerrett purchased 10,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were purchased at an average cost of $8.55 per share, with a total value of $85,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have acquired 21,000 shares of company stock worth $184,360 over the last three months. Insiders own 1.70% of the company’s stock.

Several institutional investors have recently modified their holdings of OSUR. Thrivent Financial for Lutherans boosted its holdings in OraSure Technologies by 2.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 43,801 shares of the medical instruments supplier’s stock valued at $512,000 after acquiring an additional 963 shares in the last quarter. Texas Permanent School Fund boosted its holdings in OraSure Technologies by 4.1% in the fourth quarter. Texas Permanent School Fund now owns 40,081 shares of the medical instruments supplier’s stock valued at $468,000 after acquiring an additional 1,590 shares in the last quarter. Comerica Bank boosted its holdings in OraSure Technologies by 3.2% in the first quarter. Comerica Bank now owns 60,719 shares of the medical instruments supplier’s stock valued at $632,000 after acquiring an additional 1,896 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in OraSure Technologies by 2.7% in the fourth quarter. Macquarie Group Ltd. now owns 93,544 shares of the medical instruments supplier’s stock valued at $1,093,000 after acquiring an additional 2,432 shares in the last quarter. Finally, Roble Belko & Company Inc bought a new stake in OraSure Technologies in the first quarter valued at $29,000. Hedge funds and other institutional investors own 91.51% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Recommended Story: Marijuana Stocks Future Looks Bright

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.